---

Study of efficacy of intravitreal triamcinolone acetonide (IVTA) for the treatment of refractory diabetic macular edema (DME) in type 2 diabetes mellitus patients

---

Original Article

Author Details : Pankaj Soni*, Ashutosh Kumar Singh, Suroma Joysmine Marndi

Volume : 5, Issue : 3, Year : 2019

Article Page : 401-406

https://doi.org/10.18231/j.ijceo.2019.097

Suggest article by email

Get Permission

---

Abstract

Aim: To study the efficacy of intravitreal triamcinolone acetonide (IVTA) for the treatment of refractory diabetic macular edema (DME) in type 2 diabetes mellitus patients.
Materials and Methods: A prospective, interventional, non-comparative case series. There were 13 eyes of 13 patients with refractory DME. An intravitreal injection of triamcinolone acetonide at the dose of 4 mg in 0.1 ml was administered. Best corrected visual acuity was measured at each examination. The amount of hard exudates deposition in the macula was subjectively evaluated using colour fundus photographs. Central macular thickness (CMT) was measured, on OCT.
Results: 13 patients completed 6 months or more of follow up and were included in the study. Sex distribution in the study was 12 (92.40%) males and 1 female (7.60%). There was significant improvement in the visual acuity, 2.42 ± 1 (mean ± SD) (p<0>
Conclusions: Intravitreal injection of 4 mg of triamcinolone acetonide may be beneficial for improving visual acuity in type 2 diabetes patients which have refractory diabetic macular edema.

Keywords: Diabetic Macular Edema (DME), Intra Vitreal Triamcinolone Acetonide (IVTA).

How to cite : Soni P , Singh A K, Marndi S J, Study of efficacy of intravitreal triamcinolone acetonide (IVTA) for the treatment of refractory diabetic macular edema (DME) in type 2 diabetes mellitus patients. Indian J Clin Exp Ophthalmol 2019;5(3):401-406

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.